KQ-2003 CAR T-cells
Phase 2Cell therapy
KQ-2003 CAR T-cells is one of 40 biologic programs targeting POEMS syndrome. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
282 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Belamaf
GSKPhase 3
Empliciti
Bristol-Myers SquibbPhase 3
Fludara
SanofiPhase 3
TALVEY
Johnson & JohnsonPhase 3
Sarclisa
AAzienda U.S.L. 1 di Massa e Carrara
Phase 3
Biaxin
AbbViePhase 3
Xpovio
KKaryopharm Therapeutics Inc
Phase 3
Azatiq
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Elranatamab
PfizerPhase 3
Vepesid
AAvyxa
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma2 trials
POEMS syndrome1 trial
A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS Syndrome
Not yet recruiting·NNovatim Immune Therapeutics (Zhejiang) Co., Ltd.·Phase 1·NCT06518876·21 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for KQ-2003 CAR T-cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details